Prevention of erectile dysfunction after radiotherapy for prostate cancer

• 来源期刊: 亚洲男性学杂志（英文版）
• 年，卷（期）: 2014,（6）
• 页码范围: 805-806
• 页数: 2页
• 语种: 中文
• DOI: 10.4103/1008-682X.133327

摘要

With increasing scrutiny of prostate cancer (PCa) diagnosis and treatment,much attention has been given to the morbidity caused by radical prostatectomy (RP) and/or radiotherapy (RT).One of the most common side-effects of either treatment is erectile dysfunction (ED).1 Approximately,40％ of patients will experience ED after RT for PCa.The post-RT ED causes significant patient dissatisfaction with cancer treatment as well as decrease in patient and partner psychosocial function.2 To address this issue in patients undergoing RT,Pisansky et al.3 conducted a prospective,randomized,double-blinded,placebo-controlled trial to assess the efficacy of a phosphodiesterase enzyme-5 inhibitor (PDE5i),tadalafil,as a preventive measure for patients undergoing RT for PCa and found no difference in erectile function between the control and treatment groups.